{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:55:52Z","timestamp":1791852952287,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006416","name":"Universidade Estadual De Campinas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006416","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Sodium-glucose co-transporter 2 (SGLT2) inhibitors are used in type 2 diabetes mellitus management, reducing the risk of cardiovascular and renal complications. It has been stated that bone cells do not express the SGLT2 co-transporter; however, the establishment of a direct SGLT2 expression in bone and osteoblast-like cells would provide a significant advance in our understanding of direct SGLT2i effects on bone tissue from patients with metabolic bone diseases, such as chronic kidney disease or osteoporosis. SLC5A2 gene expression was investigated in osteoblast-like and renal HK-2 cells, and in human iliac crest bone samples from healthy individuals and patients with diverse stages of CKD from total RNA by real-time PCR. Additionally, SGLT2 protein qualitative expression was evaluated by Western blot in osteoblast-like cell lysates and by immunohistochemistry in bone samples from apparently healthy individuals and patients with CKD. Statistical significance was set at\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05. SLC5A2 gene expression in osteoblast-like cells is comparable to HK-2 cells. Notably, in human bone samples, SLC5A2 was detected above threshold in both healthy individuals and patients with CKD; thus, absolute quantification of its transcript number of copies was feasible in bone samples for these conditions. SGLT2 protein was detected in osteoblast-like cells. Additionally, this protein was immunodetected in osteocytes embedded in mineralized trabecular and cortical bone samples from healthy subjects and patients with CKD. SLC5A2 gene expression and SGLT2 protein were detected in human osteoblast-like cells and bone from both healthy individuals and patients with CKD. These findings constitute an essential step toward advancing the understanding of effects, if any, of SGLT2 inhibitors on bone tissue from patients with CKD.\n                  <\/jats:p>","DOI":"10.1007\/s00223-026-01498-7","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:10:13Z","timestamp":1773364213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bone from Healthy Individuals and Patients with CKD Expresses the Sodium-Glucose Co-transporter-2 (SGLT2)"],"prefix":"10.1007","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8365-8267","authenticated-orcid":false,"given":"Lauter Eston","family":"Pelepenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciene Machado","family":"dos Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzia Naoko Shinohara","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Bueno","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1498_CR1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41574-020-0392-2","volume":"16","author":"AJ Scheen","year":"2020","unstructured":"Scheen AJ (2020) Sodium\u2013glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16:556\u2013577. https:\/\/doi.org\/10.1038\/s41574-020-0392-2","journal-title":"Nat Rev Endocrinol"},{"key":"1498_CR2","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788\u20131801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8","journal-title":"Lancet"},{"key":"1498_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2024.100851","volume":"6","author":"M Madero","year":"2024","unstructured":"Madero M, Chertow GM, Mark PB (2024) SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med 6:100851. https:\/\/doi.org\/10.1016\/j.xkme.2024.100851","journal-title":"Kidney Med"},{"key":"1498_CR4","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMc1712572","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:2099. https:\/\/doi.org\/10.1056\/NEJMc1712572","journal-title":"N Engl J Med"},{"key":"1498_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"1498_CR6","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"1498_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2024.11.013","volume":"107","author":"M Ketteler","year":"2025","unstructured":"Ketteler M, Evenepoel P, Holden RM et al (2025) Chronic kidney disease-mineral and bone disorder: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 107:405\u2013423. https:\/\/doi.org\/10.1016\/j.kint.2024.11.013","journal-title":"Kidney Int"},{"key":"1498_CR8","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","volume":"406","author":"PB Mark","year":"2025","unstructured":"Mark PB, Stafford LK, Grams ME et al (2025) Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406:2461\u20132482. https:\/\/doi.org\/10.1016\/S0140-6736(25)01853-7","journal-title":"Lancet"},{"key":"1498_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1590\/2175-8239-JBN-2019-0045","volume":"42","author":"CEM Carbonara","year":"2020","unstructured":"Carbonara CEM, Reis LMD, Quadros KRdaS et al (2020) Renal osteodystrophy and clinical outcomes: data from the Brazilian Registry of Bone Biopsies - REBRABO. J Bras Nefrol 42:138\u2013146. https:\/\/doi.org\/10.1590\/2175-8239-JBN-2019-0045","journal-title":"J Bras Nefrol"},{"key":"1498_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bone.2017.01.023","volume":"100","author":"KA Hruska","year":"2017","unstructured":"Hruska KA, Sugatani T, Agapova O, Fang Y (2017) The chronic kidney disease - Mineral bone disorder (CKD-MBD): advances in pathophysiology. Bone 100:80\u201386. https:\/\/doi.org\/10.1016\/j.bone.2017.01.023","journal-title":"Bone"},{"key":"1498_CR11","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962\u2013971. https:\/\/doi.org\/10.1038\/ki.2013.356","journal-title":"Kidney Int"},{"key":"1498_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts NB, Bilezikian JP, Usiskin K et al (2016) Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 101:157\u2013166. https:\/\/doi.org\/10.1210\/jc.2015-3167","journal-title":"J Clin Endocrinol Metab"},{"key":"1498_CR13","first-page":"139","volume":"57","author":"No authors listed","year":"2015","unstructured":"No authors listed (2015) SGLT2 inhibitors: new reports. Med Lett Drugs Ther 57:139\u2013140","journal-title":"Med Lett Drugs Ther"},{"key":"1498_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12902-024-01575-8","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, Li X, Li Y, Lei C (2024) Effects of sodium-glucose cotransporter 2 inhibitors on bone metabolism in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. BMC Endocr Disord 24:52. https:\/\/doi.org\/10.1186\/s12902-024-01575-8","journal-title":"BMC Endocr Disord"},{"key":"1498_CR15","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","volume":"14","author":"JE Blau","year":"2018","unstructured":"Blau JE, Taylor SI (2018) Adverse effects of SGLT2 inhibitors on bone health. Nat Rev Nephrol 14:473\u2013474. https:\/\/doi.org\/10.1038\/s41581-018-0028-0","journal-title":"Nat Rev Nephrol"},{"key":"1498_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","volume":"3","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI (2015) Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol 3:8\u201310. https:\/\/doi.org\/10.1016\/S2213-8587(14)70227-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1498_CR17","unstructured":"US Food and Drug Administration (2015) Safety alert on canagliflozin. In: Saf. Warn. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-revises-label-diabetes-drug-canagliflozin-invokana-invokamet. Accessed 25 Jun 2025"},{"key":"1498_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Watts NB, Usiskin K et al (2016) Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101:44\u201351. https:\/\/doi.org\/10.1210\/jc.2015-1860","journal-title":"J Clin Endocrinol Metab"},{"key":"1498_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","volume":"16","author":"J Bolinder","year":"2014","unstructured":"Bolinder J, Ljunggren \u00d6, Johansson L et al (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16:159\u2013169. https:\/\/doi.org\/10.1111\/dom.12189","journal-title":"Diabetes Obes Metab"},{"key":"1498_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.jcmg.2016.01.020","volume":"9","author":"C P\u00e9rez-Medina","year":"2016","unstructured":"P\u00e9rez-Medina C, Binderup T, Lobatto ME et al (2016) In vivo PET imaging of HDL in multiple atherosclerosis models. JACC Cardiovasc Imaging 9:950\u2013961. https:\/\/doi.org\/10.1016\/j.jcmg.2016.01.020","journal-title":"JACC Cardiovasc Imaging"},{"key":"1498_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.2215\/CJN.16171221","volume":"17","author":"A Cowan","year":"2022","unstructured":"Cowan A, Jeyakumar N, Kang Y et al (2022) Fracture risk of sodium-glucose cotransporter-2 inhibitors in chronic kidney disease. Clin J Am Soc Nephrol 17:835\u2013842. https:\/\/doi.org\/10.2215\/CJN.16171221","journal-title":"Clin J Am Soc Nephrol"},{"key":"1498_CR22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2215\/CJN.0000000000000196","volume":"18","author":"J Barreto","year":"2023","unstructured":"Barreto J, Borges C, Rodrigues TB et al (2023) Pharmacokinetic properties of dapagliflozin in hemodialysis and peritoneal dialysis patients. Clin J Am Soc Nephrol 18:1051\u20131058. https:\/\/doi.org\/10.2215\/CJN.0000000000000196","journal-title":"Clin J Am Soc Nephrol"},{"key":"1498_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023811","author":"R Adhikari","year":"2022","unstructured":"Adhikari R, Jha K, Dardari Z et al (2022) National trends in use of sodium\u2010glucose cotransporter\u20102 inhibitors and glucagon\u2010like peptide\u20101 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.121.023811","journal-title":"J Am Heart Assoc"},{"key":"1498_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cells14090668","author":"A Cuttone","year":"2025","unstructured":"Cuttone A, Cannav\u00f2 V, Abdullah RMS et al (2025) Expanding the use of SGLT2 inhibitors in T2D patients across clinical settings. Cells. https:\/\/doi.org\/10.3390\/cells14090668","journal-title":"Cells"},{"key":"1498_CR25","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436\u20131446. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"1498_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22\u201331. https:\/\/doi.org\/10.1016\/S2213-8587(20)30369-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1498_CR27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.4248\/BR201304002","volume":"1","author":"RE Tomlinson","year":"2013","unstructured":"Tomlinson RE, Silva MJ (2013) Skeletal blood flow in bone repair and maintenance. Bone Res 1:311\u2013322. https:\/\/doi.org\/10.4248\/BR201304002","journal-title":"Bone Res"},{"key":"1498_CR28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2106\/00004623-196951020-00010","volume":"51","author":"WJ Kane","year":"1969","unstructured":"Kane WJ, Grim E (1969) Blood flow to canine hind-limb bone, muscle, and skin. A quantitative method and its validation. J Bone Joint Surg Am 51:309\u2013322","journal-title":"J Bone Joint Surg Am"},{"key":"1498_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bone.2017.08.008","volume":"115","author":"CM Karner","year":"2018","unstructured":"Karner CM, Long F (2018) Glucose metabolism in bone. Bone 115:2\u20137. https:\/\/doi.org\/10.1016\/j.bone.2017.08.008","journal-title":"Bone"},{"key":"1498_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou L, Cryan EV, D\u2019Andrea MR et al (2003) Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J Cell Biochem 90:339\u2013346. https:\/\/doi.org\/10.1002\/jcb.10631","journal-title":"J Cell Biochem"},{"key":"1498_CR31","doi-asserted-by":"publisher","DOI":"10.2337\/db24-0955","author":"SB Poudel","year":"2025","unstructured":"Poudel SB, Chlebek C, Ruff RR et al (2025) Canagliflozin-induced adaptive metabolism in bone. Diabetes. https:\/\/doi.org\/10.2337\/db24-0955","journal-title":"Diabetes"},{"key":"1498_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13300-019-00724-w","volume":"11","author":"A Erythropoulou-Kaltsidou","year":"2020","unstructured":"Erythropoulou-Kaltsidou A, Polychronopoulos G, Tziomalos K (2020) Sodium-glucose co-transporter 2 inhibitors and fracture risk. Diabetes Ther 11:7\u201314. https:\/\/doi.org\/10.1007\/s13300-019-00724-w","journal-title":"Diabetes Ther"},{"key":"1498_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.918350","volume":"13","author":"B Dong","year":"2022","unstructured":"Dong B, Lv R, Wang J et al (2022) The extraglycemic effect of SGLT-2is on mineral and bone metabolism and bone fracture. Front Endocrinol (Lausanne) 13:918350. https:\/\/doi.org\/10.3389\/fendo.2022.918350","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1498_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-017-0274-5","volume":"9","author":"AGD Vianna","year":"2017","unstructured":"Vianna AGD, Sanches CP, Barreto FC (2017) Review article: effects of type 2 diabetes therapies on bone metabolism. Diabetol Metab Syndr 9:75. https:\/\/doi.org\/10.1186\/s13098-017-0274-5","journal-title":"Diabetol Metab Syndr"},{"key":"1498_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.749010","volume":"12","author":"J Shaffner","year":"2021","unstructured":"Shaffner J, Chen B, Malhotra DK et al (2021) Therapeutic targeting of SGLT2: a new era in the treatment of diabetes and diabetic kidney disease. Front Endocrinol (Lausanne) 12:749010. https:\/\/doi.org\/10.3389\/fendo.2021.749010","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1498_CR36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bone.2016.10.026","volume":"94","author":"KM Thrailkill","year":"2017","unstructured":"Thrailkill KM, Nyman JS, Bunn RC et al (2017) The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. Bone 94:141\u2013151. https:\/\/doi.org\/10.1016\/j.bone.2016.10.026","journal-title":"Bone"},{"key":"1498_CR37","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2133\/dmpk.20.452","volume":"20","author":"M Nishimura","year":"2005","unstructured":"Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20:452\u2013477. https:\/\/doi.org\/10.2133\/dmpk.20.452","journal-title":"Drug Metab Pharmacokinet"},{"key":"1498_CR38","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","volume":"82","author":"KM Thrailkill","year":"2016","unstructured":"Thrailkill KM, Clay Bunn R, Nyman JS et al (2016) SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice. Bone 82:101\u2013107. https:\/\/doi.org\/10.1016\/j.bone.2015.07.025","journal-title":"Bone"},{"key":"1498_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10727","volume":"7","author":"KRS Quadros","year":"2023","unstructured":"Quadros KRS, Roza NAV, Fran\u00e7a RA et al (2023) Advanced glycation end products and bone metabolism in patients with chronic kidney disease. JBMR Plus 7:e10727. https:\/\/doi.org\/10.1002\/jbm4.10727","journal-title":"JBMR Plus"},{"key":"1498_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1681\/ASN.2018060656","volume":"30","author":"IDB Marques","year":"2019","unstructured":"Marques IDB, Ara\u00fajo MJCLN, Graciolli FG et al (2019) A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. J Am Soc Nephrol 30:355\u2013365. https:\/\/doi.org\/10.1681\/ASN.2018060656","journal-title":"J Am Soc Nephrol"},{"key":"1498_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.yexcr.2013.12.016","volume":"322","author":"G Finesilver","year":"2014","unstructured":"Finesilver G, Bailly J, Kahana M, Mitrani E (2014) Kidney derived micro-scaffolds enable HK-2 cells to develop more in-vivo like properties. Exp Cell Res 322:71\u201380. https:\/\/doi.org\/10.1016\/j.yexcr.2013.12.016","journal-title":"Exp Cell Res"},{"key":"1498_CR42","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2337\/db20-1126","volume":"70","author":"S Zhao","year":"2021","unstructured":"Zhao S, Lo C-S, Miyata KN et al (2021) Overexpression of Nrf2 in renal proximal tubular cells stimulates sodium-glucose cotransporter 2 expression and exacerbates dysglycemia and kidney injury in diabetic mice. Diabetes 70:1388\u20131403. https:\/\/doi.org\/10.2337\/db20-1126","journal-title":"Diabetes"},{"key":"1498_CR43","doi-asserted-by":"publisher","first-page":"4857","DOI":"10.1007\/s11033-011-1281-5","volume":"39","author":"SC Tan","year":"2012","unstructured":"Tan SC, Carr CA, Yeoh KK et al (2012) Identification of valid housekeeping genes for quantitative RT-PCR analysis of cardiosphere-derived cells preconditioned under hypoxia or with prolyl-4-hydroxylase inhibitors. Mol Biol Rep 39:4857\u20134867. https:\/\/doi.org\/10.1007\/s11033-011-1281-5","journal-title":"Mol Biol Rep"},{"key":"1498_CR44","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/sj.bjc.6605851","volume":"103","author":"J Caradec","year":"2010","unstructured":"Caradec J, Sirab N, Revaud D et al (2010) Is GAPDH a relevant housekeeping gene for normalisation in colorectal cancer experiments? Br J Cancer 103:1475\u20131476. https:\/\/doi.org\/10.1038\/sj.bjc.6605851","journal-title":"Br J Cancer"},{"key":"1498_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-603","volume":"14","author":"C Guillot","year":"2014","unstructured":"Guillot C, Favaudon V, Herceg Z et al (2014) PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitrohepatocellular carcinoma models. BMC Cancer 14:603. https:\/\/doi.org\/10.1186\/1471-2407-14-603","journal-title":"BMC Cancer"},{"key":"1498_CR46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bone.2004.03.012","volume":"35","author":"LS Stilgren","year":"2004","unstructured":"Stilgren LS, Rettmer E, Eriksen EF et al (2004) Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-\u03bab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 35:256\u2013265. https:\/\/doi.org\/10.1016\/j.bone.2004.03.012","journal-title":"Bone"},{"key":"1498_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bdq.2015.01.005","volume":"3","author":"D Svec","year":"2015","unstructured":"Svec D, Tichopad A, Novosadova V et al (2015) How good is a PCR efficiency estimate: recommendations for precise and robust qPCR efficiency assessments. Biomol Detect Quantif 3:9\u201316. https:\/\/doi.org\/10.1016\/j.bdq.2015.01.005","journal-title":"Biomol Detect Quantif"},{"key":"1498_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gnh053","volume":"32","author":"S Swillens","year":"2004","unstructured":"Swillens S, Goffard J-C, Mar\u00e9chal Y (2004) Instant evaluation of the absolute initial number of cDNA copies from a single real-time PCR curve. Nucleic Acids Res 32:e56. https:\/\/doi.org\/10.1093\/nar\/gnh053","journal-title":"Nucleic Acids Res"},{"key":"1498_CR49","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1128\/AEM.07878-11","volume":"78","author":"R Brankatschk","year":"2012","unstructured":"Brankatschk R, Bodenhausen N, Zeyer J, B\u00fcrgmann H (2012) Simple absolute quantification method correcting for quantitative PCR efficiency variations for microbial community samples. Appl Environ Microbiol 78:4481\u20134489. https:\/\/doi.org\/10.1128\/AEM.07878-11","journal-title":"Appl Environ Microbiol"},{"key":"1498_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1128\/AEM.01581-10","volume":"77","author":"K Oliwa-Stasiak","year":"2011","unstructured":"Oliwa-Stasiak K, Kolaj-Robin O, Adley CC (2011) Development of real-time PCR assays for detection and quantification of Bacillus cereus group species: differentiation of B. weihenstephanensis and rhizoid B. pseudomycoides isolates from milk. Appl Environ Microbiol 77:80\u201388. https:\/\/doi.org\/10.1128\/AEM.01581-10","journal-title":"Appl Environ Microbiol"},{"key":"1498_CR51","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.kint.2019.06.007","volume":"96","author":"MJCLN Ara\u00fajo","year":"2019","unstructured":"Ara\u00fajo MJCLN, Bacelar Marques ID, Graciolli FG et al (2019) Comparison of serum levels with bone content and gene expression indicate a contradictory effect of kidney transplantation on sclerostin. Kidney Int 96:1100\u20131104. https:\/\/doi.org\/10.1016\/j.kint.2019.06.007","journal-title":"Kidney Int"},{"key":"1498_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02653-20","volume":"87","author":"W Van Holm","year":"2021","unstructured":"Van Holm W, Ghesqui\u00e8re J, Boon N et al (2021) A viability quantitative PCR dilemma: are longer amplicons better? Appl Environ Microbiol 87:e0265320. https:\/\/doi.org\/10.1128\/AEM.02653-20","journal-title":"Appl Environ Microbiol"},{"key":"1498_CR53","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/bmb.21552","volume":"49","author":"R Harshitha","year":"2021","unstructured":"Harshitha R, Arunraj DR (2021) Real-time quantitative PCR: a tool for absolute and relative quantification. Biochem Mol Biol Educ 49:800\u2013812. https:\/\/doi.org\/10.1002\/bmb.21552","journal-title":"Biochem Mol Biol Educ"},{"key":"1498_CR54","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1016\/j.csbj.2023.07.034","volume":"21","author":"J Wang","year":"2023","unstructured":"Wang J, Yu X, Cao X et al (2023) GAPDH: a common housekeeping gene with an oncogenic role in pan-cancer. Comput Struct Biotechnol J 21:4056\u20134069. https:\/\/doi.org\/10.1016\/j.csbj.2023.07.034","journal-title":"Comput Struct Biotechnol J"},{"key":"1498_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1590\/S1516-89132013000100019","volume":"56","author":"EdeL Rebou\u00e7as","year":"2013","unstructured":"Rebou\u00e7as EdeL, Costa JJdoN, Passos MJ et al (2013) Real time PCR and importance of housekeepings genes for normalization and quantification of mRNA expression in different tissues. Braz Arch Biol Technol 56:143\u2013154. https:\/\/doi.org\/10.1590\/S1516-89132013000100019","journal-title":"Braz Arch Biol Technol"},{"key":"1498_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12938-023-01096-w","volume":"22","author":"J Dvorakova","year":"2023","unstructured":"Dvorakova J, Wiesnerova L, Chocholata P et al (2023) Human cells with osteogenic potential in bone tissue research. Biomed Eng Online 22:33. https:\/\/doi.org\/10.1186\/s12938-023-01096-w","journal-title":"Biomed Eng Online"},{"key":"1498_CR57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/jisp.jisp_503_23","volume":"28","author":"AS Dolly","year":"2024","unstructured":"Dolly AS, Rajula PB, Shankar PLR et al (2024) Osteogenic assessment of leukocyte platelet-rich fibrin and injectable platelet-rich fibrin in the human osteosarcoma MG - 63 cell line in chronic periodontitis patients: an in vitro study. J Indian Soc Periodontol 28:192\u2013196. https:\/\/doi.org\/10.4103\/jisp.jisp_503_23","journal-title":"J Indian Soc Periodontol"},{"key":"1498_CR58","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00774-007-0788-2","volume":"26","author":"SA Gomes","year":"2008","unstructured":"Gomes SA, dos Reis LM, de Oliveira IB et al (2008) Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry. J Bone Miner Metab 26:110\u2013113. https:\/\/doi.org\/10.1007\/s00774-007-0788-2","journal-title":"J Bone Miner Metab"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01498-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01498-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01498-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:49:51Z","timestamp":1781639391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01498-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1498"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01498-7","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has a conflict of interest concerning this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"39"}}